CD28 and hepatocellular carcinoma: A small study of 13 patients with incurable HCC, treated with a glypican-3 specific CAR T cells (lentivirally transduced, expressing CD3-zeta and a CD28 intracellular domain), provided revealing insights into the potential of this approach [88].